CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on understanding drug resistance in cancer treatments, particularly in BRCA2-deficient tumors. It employs advanced genetic techniques and imaging to investigate mechanisms of resistance and aims to improve treatment strategies for cancer patients.
Despite the existence of various novel anti-cancer treatments, drug resistance remains a major cause of death in patients with disseminated cancer.
To increase specificity and efficacy, modern treatment strategies in molecular oncology employ the “synthetic lethality” concept.
An example are BRCA1/2-deficient breast and ovarian cancers that lack DNA repair by homologous recombination (HR).
Due to this defect, tumor cells rely more on other DNA repair pathways.
When such alternative pathways are…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
